Paper20549698
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L and 3 others. Int J Cancer, 2011. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Papers, record 20549698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20549698
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Hormonal | Major topic |
| Breast Neoplasms | Major topic |
| Estradiol | Major topic |
| Tamoxifen | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Apoptosis | |
| Blotting, Western | |
| Cell Cycle | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Drug Resistance, Neoplasm | |
| ErbB Receptors | |
| Estrogen Antagonists | |
| Estrogen Receptor alpha | |
| Estrogens | |
| Female | |
| Flow Cytometry | |
| Fulvestrant | |
| Humans | |
| Immunoenzyme Techniques | |
| RNA, Messenger | |
| RNA, Small Interfering | |
| Erb-b2 Receptor Tyrosine Kinases | |
| Reverse Transcriptase Polymerase Chain Reaction |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 07-0606 | Worldwide Cancer Research | United Kingdom | PubMed |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41939469 | Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis. | Front Oncol | 2026 | https://conductscience.org/library/papers/41939469 | PubMed |
| 41160600 | p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/41160600 | PubMed |
| 41026455 | Genetic and epigenetic contribution to tamoxifen resistance in breast cancer, concepts to drive therapeutic strategies. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41026455 | PubMed |
| 40072091 | Sex Disparities in P53 Regulation and Functions: Novel Insights for Personalized Cancer Therapies. | Cells | 2025 | https://conductscience.org/library/papers/40072091 | PubMed |
| 39191497 | P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells. | Cancer Genomics Proteomics | 2024 | https://conductscience.org/library/papers/39191497 | PubMed |
| 37627092 | BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37627092 | PubMed |
| 34441794 | Invasion and Metastasis as a Central Hallmark of Breast Cancer. | J Clin Med | 2021 | https://conductscience.org/library/papers/34441794 | PubMed |
| 34307167 | Role of Sex in the Therapeutic Targeting of p53 Circuitry. | Front Oncol | 2021 | https://conductscience.org/library/papers/34307167 | PubMed |
| 32695778 | Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32695778 | PubMed |
| 32061310 | TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. | Trends Cancer | 2020 | https://conductscience.org/library/papers/32061310 | PubMed |
| 29991800 | Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX. | Oncogene | 2018 | https://conductscience.org/library/papers/29991800 | PubMed |
| 27503997 | Somatic TP53 Mutations in the Era of Genome Sequencing. | Cold Spring Harb Perspect Med | 2016 | https://conductscience.org/library/papers/27503997 | PubMed |
| 23865427 | The p53-estrogen receptor loop in cancer. | Curr Mol Med | 2013 | https://conductscience.org/library/papers/23865427 | PubMed |
| 23372829 | Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential. | PLoS One | 2013 | https://conductscience.org/library/papers/23372829 | PubMed |
| 23079576 | Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway. | Br J Cancer | 2012 | https://conductscience.org/library/papers/23079576 | PubMed |
| 21761402 | Early onset HER2-positive breast cancer is associated with germline TP53 mutations. | Cancer | 2012 | https://conductscience.org/library/papers/21761402 | PubMed |
| 21760703 | TP53 status and response to treatment in breast cancers. | J Biomed Biotechnol | 2011 | https://conductscience.org/library/papers/21760703 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CDKN1A | 1026 | PubTator's text mining | https://conductscience.org/library/genes/1026 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| GADD45A | 1647 | PubTator's text mining | https://conductscience.org/library/genes/1647 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK3 | 5595 | PubTator's text mining | https://conductscience.org/library/genes/5595 | NCBI Gene |
| TFF1 | 7031 | PubTator's text mining | https://conductscience.org/library/genes/7031 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20549698
GET https://conductscience.org/api/papers/v1/20549698/authors